HaemaLogiX
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 William St Ste 204, Woolloomooloo, Ne...Website
www.haemalogix.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About HaemaLogiX
Founded in 2014, HaemaLogiX Pty Ltd is a clinical stage biotech developing novel immuno-oncology and immune therapies for patients with blood cancers. The Company is based in New South Wales, Australia.Explore more
HaemaLogiX Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HaemaLogiX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if HaemaLogiX has recently received funding, and reach out quickly before it becomes old news!
Check out if HaemaLogiX is spiking on competitors!
Click to see if HaemaLogiX had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
HaemaLogiX, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at HaemaLogiX
Product Launch: Get notified when HaemaLogiX launches new products
Funding: Get notified immidiatlly once HaemaLogiX has new funding data
Earning: See what the market has to say on HaemaLogiX recently announced quarterly report
Recommended Actions
Find VP level buyers at HaemaLogiX
Find 3 more new buyers
Compare Similar Companies to HaemaLogiX
Compare insights from companies similar to HaemaLogiX, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
HaemaLogiX is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HaemaLogiX is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HaemaLogiX.
HaemaLogiX financials insights
Gather financial insights about HaemaLogiX, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$10M
HaemaLogiX Tech Stack
A closer look at the technologies used by HaemaLogiX
See more technologies
Most Recent Scoops
Lateral Move
Executive Move
Board of Directors
New Hire
Executive Move
Board of Directors
Funding
Funding
HaemaLogiX News & Media
HaemaLogiX welcomes former Australian Federal Minister for Health Professor the Hon Greg Hunt to the company board as Non-Executive Director
SYDNEY, May 20, 2024 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech developing novel immunotherapies for patients with blood cancers and B-cell diseases, is pleased to announce the appointment of Professor the Hon Greg Hunt, former Australian Federal Minister for Health, to the HaemaLogiX Board as a Non-Executive Director. This appointment marks the first corporate directorship that Prof Hunt has accepted since completing his period as Minister for Health. As the Federal Minister for HHaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
SYDNEY, Nov. 13, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his...HaemaLogiX and Peter MacCallum Cancer Centre Announce Myeloma CAR-T Phase I Clinical Trial Agreement
HaemaLogiX and Peter MacCallum Cancer Centre have entered a collaboration agreement to develop and conduct the first Phase I human trial of HaemaLogiX's CAR-T cell therapy in patients with kappa-type myeloma The agreement is the culmination of previous preclinical research collaboration...HaemaLogiX Announces Positive Final Results from KappaMab Combination Phase IIb Myeloma Trial
Significant improvement in Overall Response Rate (83%) compared with matched case control group (45%). Significant overall survival advantage, with a 46% reduction in the risk of death. Excellent safety profile and significant efficacy bolster HaemaLogiX's plan to progress further...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding HaemaLogiX
Sign Up For FreeTo access detailed company insights
Founded in 2014, HaemaLogiX Pty Ltd is a clinical stage biotech developing novel immuno-oncology and immune therapies for patients with blood cancers. The Company is based in New South Wales, Australia.... Read More
